BioRestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Key Stats

• Today's Range: $1.52 to $1.59
• 50-Day Range: $1.46 to $1.92
• 52-Week Range: $1.03 to $3.67
• Volume: 8,271 shs
• Average Volume: 799,412 shs
• Market Capitalization: $10.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTX shares have decreased by 10.3% and is now trading at $1.56.
View the best growth stocks for 2024 here.

How were BioRestorative Therapies' earnings last quarter?

BioRestorative Therapies, Inc. (OTCMKTS:BRTX) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.06. The company earned $0.09 million during the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 13,728.83% and a negative trailing twelve-month return on equity of 120.47%.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies's stock reverse split on the morning of Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioRestorative Therapies investors own include Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), Onconova Therapeutics (ONTX) and American Graphite Technologies (AGIN).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/02/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:BRTX
• CUSIP: N/A
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: (631) 760-8100
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,500,000.00
• Net Margins: -13,728.83%
• Pretax Margin: -13,728.83%
• Return on Equity: -120.47%
• Return on Assets: -114.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.81
• Quick Ratio: 14.81

Sales & Book Value

• Annual Sales: $174,100.00
• Price / Sales: 62.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 6,920,000
• Free Float: 3,660,000
• Market Cap: $10.80 million
• Optionable: Not Optionable
• Beta: 63.02